Impact of viral eradication with sofosbuvir-based therapy on the outcome of post-transplant hepatitis C with severe fibrosis

Liver International

Volumn 37, Issue 1, 2017, Pages 62-70

  Martini, Silvia ^a   Sacco, Marco ^a   Strona, Silvia ^a   Arese, Daniele ^a   Tandoi, Francesco ^a   Dell Olio, Dominic ^a   Stradella, Davide ^a   Cocchis, Donatella ^a   Mirabella, Stefano ^a   Rizza, Giorgia ^a   Magistroni, Paola ^a   Moschini, Pamela ^a   Ottobrelli, Antonio ^a   Amoroso, Antonio ^a   Rizzetto, Mario ^a   Salizzoni, Mauro ^a   Saracco, Giorgio M ^a   Romagnoli, Renato ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

direct acting antivirals; HCV recurrence; liver transplantation; non invasive fibrosis tests; survival

Indexed keywords

ASPARTATE AMINOTRANSFERASE; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; ANTIVIRUS AGENT;

ADULT; AGED; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELASTOGRAPHY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION; LIVER GRAFT; LIVER STIFFNESS; MAJOR CLINICAL STUDY; MALE; RASH; RECURRENT DISEASE; SEPSIS; THROMBOCYTE; VIRAL CLEARANCE; COMBINATION DRUG THERAPY; COMPLICATION; GENOTYPE; HEPACIVIRUS; ITALY; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MIDDLE AGED; PATHOLOGY; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY;

AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ELASTICITY IMAGING TECHNIQUES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; ITALY; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RECURRENCE; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; SUSTAINED VIROLOGIC RESPONSE;

EID: 84979645449     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13193     Document Type: Article

References (22)

1. Adam R, Karam V, Delvart V. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57: 675–88.
2. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889–96.
3. Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology 2012; 142: 1373–83.
4. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274–87.
5. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78–86.
6. European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199–236.
7. Forns X, Charlton M, Denning J, et al. Sofosbuvir compassionate use program for patients with severe recurrent hepatitis C after liver transplantation. Hepatology 2015; 61: 1485–94.
8. Brown RS Jr, O'Leary JG, Reddy KR, et al. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: real world experience from HCV-TARGET. Liver Transpl 2016; 22: 24–33.
9. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835–47.
10. Romagnoli R, Martini S, Tandoi F, et al. Early reduced liver graft survival in hepatitis C recipients identified by two combined genetic markers. Transpl Int 2016; 29: 1070–84.
11. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest. Hepatology 2007; 46: 32–6.
12. Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518–26.
13. Salizzoni M, Franchello A, Smedile A, et al. Marginal grafts: finding the correct treatment for fatty livers. Transpl Int 2003; 16: 486–93.
14. Russo FP, Zanetto A, Burra P. Timing for treatment of HCV recurrence after liver transplantation: the earlier the better. Transpl Int 2016; 29: 694–7.
15. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 2015; 149: 649–59.
16. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology 2015; 148: 108–17.
17. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46: 923–7.
18. Kobayashi T, Hige S, Terashita K, et al. Anemia and thrombocytosis induced by ribavirin monotherapy in patients with chronic hepatitis C. J Gastroenterol 2012; 47: 1228–37.
19. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303–13.
20. European Association for the Study of the Liver. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237–64.
21. ® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 2013; 59: 251–6.
22. Foster GR, Irving WL, Cheung MC, et al. HCV Research UK. Cohort study of the impacts of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016; 64: 1224–31.